ABX-464
- Generic Name
- ABX-464
- Drug Type
- Small Molecule
- Chemical Formula
- C16H10ClF3N2O
- CAS Number
- 1258453-75-6
- Unique Ingredient Identifier
- 26RU378B9V
- Background
ABX-464 is under investigation in clinical trial NCT03905109 (Safety Evaluation of ABX464 in Patients With Moderate to Severe Active Crohn's Disease).
Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Abivax S.A.
- Registration Number
- NCT03905109
- Locations
- 🇧🇪
University Hospitals Leuven - campus Gasthuisberg, Leuven, Belgium
Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 22
- Registration Number
- NCT03368118
- Locations
- 🇧🇪
Department of Gastroenterology - University hospitals Leuven, Leuven, Belgium
ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 32
- Registration Number
- NCT03093259
- Locations
- 🇦🇹
Univ.-Klinik für Innere Medizin I, Innsbruck, Austria
🇨🇿Klinické centrum ISCARE, Praha, Czechia
🇫🇷CHU de Nantes, Nantes, France
ABX464 First in Man Study
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 24
- Registration Number
- NCT02792686
- Locations
- 🇫🇷
Centre Cap, Montpellier, France
ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 30
- Registration Number
- NCT02735863
- Locations
- 🇧🇪
C.H.U. Saint-Pierre, Bruxelles, Belgium
🇧🇪Ghent University Hospital, Ghent, Belgium
🇧🇪CHU Sart Tilman, Liège, Belgium
Safety, PK and PD Study of ABX464 in Untreated HIV Patients
- Conditions
- Human Immunodeficiency Virus Infections
- Interventions
- Other: Placebo
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 70
- Registration Number
- NCT02452242
- Locations
- 🇲🇺
CAP Research Ltd, Curepipe, Mauritius
🇹ðŸ‡Chiang Mai University, Chiang Mai, Thailand
🇹ðŸ‡Siriraj Hospital, Mahidol University, Bangkok, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.